Kappa-opioid receptor ligands

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 12, 2004, Pages 1725-1741

  Husbands, Stephen M ^a  

^a University of Bath   (United Kingdom)

Author keywords

opioid; Agonist; Antagonist; Mixed agonists; Therapeutic

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; 3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; 4,5 EPOXYINDOLOMORPHINAN DERIVATIVE; ACETAMIDE DERIVATIVE; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTINOCICEPTIVE AGENT; ASIMADOLINE; BENZOTHIAZOLINE DERIVATIVE; CYCLAZOCINE; CYCLORPHAN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; KETAZOCINE; LEVALLORPHAN; LEVORPHANOL; LIGAND; MORPHINAN DERIVATIVE; MORPHINE; MR 2003; N (TETRAHYDROFURFURYL)NORMETAZOCINE; NALFURAFINE; NALTREXONE; NALTRINDOLE; NORBINALTORPHIMINE; OXYMORPHONE; PIPERIDINE DERIVATIVE; PYRIDONE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ANXIETY; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIURESIS; DRUG ANTAGONISM; DRUG DEPENDENCE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPHORIA; EYE PAIN; FATIGUE; HUMAN; HYPERALGESIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; NAUSEA; NONHUMAN; PRURITUS; PUPIL DISEASE; RESPIRATION DEPRESSION; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SEPTICEMIA; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 10344221014     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.12.1725     Document Type: Review

References (72)

1. McCAWLEY EL, HART ER, MARSH DF: The preparation of N-allylnormorphine. J. Am. Chem. Soc. (1941) 63:314-314.
2. LASAGNE L, BEECHER H: The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J. Pharmacol. Exp. Ther. (1954) 122:356-363.
3. MARTIN WR: Opioid antagonists. Pharmacol. Rev. (1967) 19:463-521.
4. PEARL J, HARRIS LS: Inhibition of writhing by narcotic antagonists. J. Pharmacol. Exp. Ther. (1966) 154:319-323.
5. LORD JA, WATERFIELD AA, HUGHES J, KOSTERLITZ HW: Endogenous opioid peptides: multiple agonists and receptors. Nature (1977) 267:495-499.
6. MARTIN WR, FRASER HF, GORODETZKY CW, ROSENBERG DE: Studies of the dependence producing potential of the narcotic antagonist 2-cyclopropylmethyl-2′-hydroxy-5,9-dimethyl-6,7-benzmorphan. J. Pharmacol. Exp. Ther. (1965) 150:426-436.
7. JASINSKI DR, GRIFFITH JD, PEVNICK JS, CLARK SC: Progress report on studies from the clinical pharmacology section of the Addiction Research Center. Proceedings of the 37th Meeting of the Committee on Problems of Drug Dependence. (1975):136-161.
8. PFEIFFER A, BRANTL V, HERZ A: Psychotomimesis mediated by κ-opiate receptors. Science (1986) 233:774-776.
9. REECE PA, SEDMAN AJ, ROSE S, WRIGHT DS, DAWKINS R, RAJAGOPALAN R: Diuretic effects, pharmacokinetics, and safety of a new centrally acting κ-opioid agonist (CI-977) in humans. J. Clin. Pharmacol. (1994) 34:1126-1132.
10. CHAPPELL PB, LECKMAN JF, SCAHILL LD, HARDIN MT, ANDERSON G, COHEN DJ: Neuroendocrine and behavioural effects of the selective κ-agonist spiradoline in Tourette's syndrome: a pilot study. Psychiatry Res. (1993) 47:267-280.
11. PANDE AC, PYKE RE, GREINER M, COOPER SA, BENJAMIN R, PIERCE MW: Analgesic efficacy of the κ-receptor agonist, enadoline, in dental surgery pain. Clin. Neuropharmacol. (1996a) 19:92-97.
12. PANDE AC, PYKE RE, GREINER M, WIDEMAN GL, BENJAMIN R, PIERCE MW: Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. Clin. Neuropharmacol. (1996b) 19:451-456.
13. WALSH SL, STRAIN EC, ABREU ME, BIGELOW GE: Enadoline, a selective κ-opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacol. (2001) 157:151-162.
14. CHEN T-Y, GOYAGI T, TOUNG TJK et al: Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats. Stroke (2004) 35:1180-1185.
15. MERCADANTE S, ARCURI E: Opioids and renal function. J. Pain (2004) 5:2-19.
16. KO MCH, LEE H, SONG MS et al.: Activation of κ-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J. Pharmacol. Exp. Ther. (2003) 305:173-179.
17. KUMAGAI H, SARUTA T, MATSUKAWA S, UTSUMI J: Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. Basic Clin. Dermatol. (2004) 27:279-286.
18. MARIN C, BOVE J, BONASTRE M, TOLOSA E: Effect of acute and chronic administration of U50,488, a κ-opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa. Exp. Neurology (2003) 183:66-73.
19. GHELARDINI C, GALEOTTI N, DI CESARE MANNELLI L, CAPPELLI A, ANZINI M, BARTOLINI A: Antiamnesic effect of the two novel κ-opioid agonists, VA-100 and VA-101, in the mouse passive avoidance test. Drug Dev. Res. (2001) 54:12-18.
20. NEGUS SS, MELLO NK, PORTOGHESE PS, LIN CE: Effects of κ-opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. (1997) 282:44-55.
21. MELLO NK, NEGUS SS: Effects of κ-opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J. Pharmacol. Exp. Ther. (1998) 286:812-824.
22. GLICK SD, MAISSONEUVE IM, RAUCCI J, ARCHER S: κ-Opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. (1995) 681:147-152.
23. BIDLACK JM, COHEN DJ, MCLAUGHLIN JP, LOU R, YE Y, WENTLAND MP: 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan. J. Pharmacol. Exp. Ther. (2002) 302:374-380
24. SUZUKI T, SHIOZAKI Y, MASUKAWA Y, MISAWA M, NAGASE H: The role of μ- and κ-opioid receptors in cocaine-induced conditioned place preference. Jpn. J. Pharmacol. (1992) 58:435-442.
25. TZAFERIS JA, MCGINTY JF: κ-Opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum. Mol. Brain Res. (2001) 93:27-35.
26. UKAI M, MIZUTANI M, KAMEYAMA T: Opioid peptides selective for receptor types modulate cocaine-induced behavioural responses in mice. Yakubutsu Seishin Kodo (1994) 14:153-159.
27. CRAWFORD CA, MCDOUGALL SA, BOLANOS CA, HALL S, BERGER SP: The effects of the κ-agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviours and Fos immunoreactivity. Psychopharmacology (1995) 120:392-399.
28. SHIPPENBERG TS, LEFEVOUR A, HEIDBREDER CH: κ-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. (1996) 276:545-554.
29. MORI T, NOMURA M, NAGASE H, SUZUKI T: Effects of newly synthesised κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology (2002) 161:17-22.
30. MELLO NK, NEGUS SS: Interactions between κ-opioid agonists and cocaine - preclinical studies. New medications for drug abuse. Ann. NY Acad. Sci. (2000) 909:104-132.
31. COSGROVE KP, CARROLL ME: Effects of bremazocine on self-administration of smoked cocaine base and orally delivered ethanol, phencyclidine, saccharin, and food in rhesus monkeys: A behavioural economic analysis. J. Pharmacol. Exp. Ther. (2002) 301 993-1002.
32. PRESTON KI, UMBRICHT A, SCHROEDER JR, ABREU M, PICKWORTH WB: Cyclazocine: comparison to hydromorphone and interaction with cocaine. Drug Med. Depend. (2001) 63(Suppl.1):S126.
33. METZGER TG, PATERLINI MG, PORTOGHESE PS, FERGUSON DM: Application of the message-address concept of the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem. Res. (1996) 21:1287-1294.
34. SUBRAMANIAN G, PATERLINI MG, LARSON DL, PORTOGHESE PS, FERGUSON DM: Conformational analysis and automated receptor docking of selective arylacetamide-based κ-opioid agonists. J. Med. Chem. (1998) 41:4777-4789.
35. HOLZGRABE U, BRANDT W: Mechanism of action of the diazabicyclononanone-type κ-agonists. (2003) 46:1383-1389.
36. SEMPLE G, ANDERSON BM, CHHAJLANI V et al.: 3-Aryl pyridone derivatives. Potent and selective κ-opioid receptor agonists. Bioorg. Med. Chem. Lett (2002) 12:197-200.
37. SEMPLE G, ANDERSON BM, CHHAJLANI V et al.: Synthesis and biological activity of κ-opioid receptor agonists. Part 2: Preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods. Bioorg. Med. Chem. Lett. (2003) 13:1141-1145.
38. SHARMA SK, JONES RM, METZGER TG et al.: Transformation of a κ-opioid receptor antagonist to a κ-agonist by transfer of a guanidinium group from the 5′- to 6′-position of naltrindole. J. Med. Chem. (2001) 44: 2073-2079.
39. DONDIO G, RONZONI S, PETRILLO P: Non-peptide δ-opioid agonists and antagonists. Exp. Opin. Ther. Patents (1997) 7:1075-1098.
40. TJØLSEN A, BERGE O-G, HUNSKAAR S, ROSLAND JH, HOLE K: The formalin test: an evaluation of the method. Pain (1992) 51 5-17.
41. WHEELER-ACE TO H, COWAN A: Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacol. (1991) 104:35-44.
42. KUMAR V, MARELLA MA, CORTES-BURGOS L et al.: Arylacetamides as peripherally restricted κ-opioid receptor agonists. Bioorg. Med. Chem. Lett. (2000) 10:2567-2570.
43. SHAW JS, CARROLL JA, ALCOC P, MAIN BG: ICI 204448: a κ-opioid agonist with limited access to the CNS. Br J. Pharmacol. (1989) 96:986-992.
44. KEITA H, KAYSER V, GUILBAUD G: Antinociceptive effect of a κ-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI-204448) in a rat model of mononeuropathy. Eur. J. Pharmacol. (1995) 277: 275-280.
45. WENTLAND MP, LOU R, YE Y et al.: 8-Carboxamidocyclazocine analogues: Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Bioorg. Med. Chem. Lett. (2001) 11:623-626.
46. WENTLAND MP, YE Y, CIOFFI C et al.: Synthesis and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. J. Med. Chem. (2003) 46:838-849.
47. WENTLAND MP, DUAN W, COHEN DJ, BIDLACK JM: Selective protection and functionalization of morphine: Synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives. J. Med. Chem. (2000) 43:3558-3565.
48. WENTLAND MP, LOU R, DEHNHARDT CM et al.: 3-Carboxamido analogues of morphine and naltrexone: Synthesis and opioid receptor binding properties. Bioorg. Med. Chem. Lett. (2001) 11 1717-1721.
49. BIDLACK JM, COHEN DJ, MCLAUGHLIN JP et al.: 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan. J. Pharmacol. Exp. Ther. (2002) 302:374-380.
50. NEUMEYER JL, GU X-H, VAN VLIET LA et al.: Mixed κ-agonists and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: Synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg. Med. Chem. Lett. (2001) 11: 2735-2740.
51. ZHANG A, XIONG W, BIDLACK JM et al.: 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed κ and μ -opioid ligands: Synthesis and biological evaluation of their binding affinity at opioid receptors. J. Med. Chem. (2004) 47:165-174.
52. PORTOGHESE PS, LIPKOWSKI AW, TAKEMORI AE: Binaltorphimine and nor-binaltorphimine, potent and selective κ-opioid receptor antagonists. Life Sci. (1987) 40:1287-1292.
53. STEVENS WC JR, JONES RM, SUBRAMANIAN G et al.: Potent and selective indolomorphinan antagonists of the κ-opioid receptor. J. Med. Chem. (2000) 43:2759-2769.
54. SCHWYZER R: A short introductory review. Ann. NY Acad. Sci. (1997) 247:3-26.
55. PORTOGHESE PS: From models to molecules: Opioid receptor dimers, bivalent ligands and selective opioid receptor probes. J. Med. Chem. (2001) 44: 2259-2269.
56. THOMAS JB, ATKINSON RN, ROTHMAN RB et al.: Identification of the first trans-(3R,4R -dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid κ-receptor antagonist activity. J. Med. Chem. (2001) 44:2687-2690.
57. THOMAS JB, ATKINSON RN, VINSON NA et al.: Identification of (3R)-7-hydroxy-N-((1S -1-{[3R,4R -4-(3-hydroxyphenyl)-3,4-dimethyl-1- piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3- isoquinolinecarboxamide as a novel potent and selective opioid κ-receptor antagonist. J. Med. Chem. (2003) 46:3127-3137.
58. ZIMMERMAN DM, NICKANDER R, HORNG JS, WONG DT: New structural concepts for structural antagonists defined in a 4-phenylpiperidine series. Nature (1978) 275: 332-334.
59. THOMAS JB, ATKINSON RN, NAMDEV N et al.: Discovery of an opioid κ-receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphans. J. Med. Chem. (2002) 45: 3524-3530.
60. XU W, HUANG L-F, BAUER L, BHARGAVA HN, DUNN WJ III: Synthesis and opiate receptor binding properties of 17-methyl-6,7-dehydro-3,14-dihydroxy-4,5α-epoxy-6,7:4′ ,5′- pyrimidinomorphinans. Bioorg. Med. Chem. Lett. (1991) 9:3375-3380.
61. KO MCH, LEE H, SONG MS et al.: Activation of κ-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J. Pharmacol. Exp. Ther. (2003) 305: 173-179.
62. KO MCH, SONG MS, EDWARDS T et al.: The role of central μ opioid receptors in opioid-induced itch in primates. J. Pharmacol. Exp. Ther. (2004) 310:169-176.
63. TOGASHI Y, UMEUCHI H, OKANO K et al.: Antipruritic activity of the κ-opioid receptor agonist, TRK-820. Eur. J. Pharmacol. (2002) 435:259-264.
64. GHONIEM GM, SHAABAN AM, CLARKE MR: Irritable bladder syndrome in an animal model: a continuous monitoring study. Neurourol. Urodyn. (1995) 14:657-665.
65. MAGUE SD, PLIAKAS AM, TODTENKOPF MS et al.: Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. (2003) 305 323-330.
66. BARBER A, GOTTSCHLICH R: Novel developments with selective, non-peptidic κ-opioid receptor agonists. Exp. Opin. Investig. Drugs (1997) 6:1351-1368.
67. MACHELSKA H, PFLUGER M, WEBER W et al. Peripheral effects of the κ-opioid agonist EMD-61753 on pain and inflammation in rats and humans. J. Pharmacol. Exp. Ther. (1999) 290:354-361.
68. 2): A peripheral efficacious κ opioid agonist with unprecedented selectivity. J. Pharmacol. Exp. Ther. (2004) 310:326-333.
69. RIVIERE PJ: Peripheral κ-opioid agonists for visceral pain. Br. J. Pharmacol. (2004) 141:1331-1334.
70. EISENACH JC, CARPENTER R, CURRY R: Analgesia from a peripherally active κ-opioid receptor agonist in patients with chronic pancreatitis. Pain (2003) 101:89-95.
71. MARTIN WR, GORODETZKY CW, McLANE TK: An experimental study in the treatment of narcotic addicts with cyclazocine. Clin. Pharmacol. Ther. (1966) 455-464.
72. Buprenorphine. Combating Drug Abuse with a Unique Opioid. Cowan A, Lewis JW (Eds), Wiley-Liss, New York (1995):326.